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Introduction: The data on long COVID in children is scarce since children
and adolescents are typically less severely affected by acute COVID-19. This
study aimed to identify the long-term consequences of SARS-CoV-2 infection in
children, and to compare the persistent symptom spectrum between COVID-19 and
community-acquired infections of other etiologies.
Methods: This was an ambidirectional cohort study conducted at the Children’s Clinical
University Hospital in Latvia. The study population of pediatric COVID-19 patients and
children with other non-SARS-CoV-2-community-acquired infections were invited to
participate between July 1, 2020, and April 30, 2021.
Results: In total, 236 pediatric COVID-19 patients were enrolled in the study.
Additionally, 142 comparison group patients were also enrolled. Median follow-up time
from acute symptom onset was 73.5 days (IQR; 43–110 days) in the COVID-19 patient
group and 69 days (IQR, 58–84 days) in the comparison group. Most pediatric COVID-19
survivors (70%, N = 152) reported at least one persistent symptom, but more than
half of the patients (53%, N = 117) noted two or more long-lasting symptoms. The
most commonly reported complaints among COVID-19 patients included persistent
fatigue (25.2%), cognitive sequelae, such as irritability (24.3%), and mood changes
(23.3%), as well as headaches (16.9%), rhinorrhea (16.1%), coughing (14.4%), and
anosmia/dysgeusia (12.3%). In addition, 105 (44.5%) COVID patients had persistent
symptoms after the 12-week cut-off point, with irritability (27.6%,N= 29), mood changes
(26.7%, N = 28), and fatigue (19.2%, N = 20) being the most commonly reported
ones. Differences in symptom spectrum among the various age groups were seen.
Logistic regression analysis showed that long-term persistent symptoms as fever, fatigue,
rhinorrhea, loss of taste and/or smell, headaches, cognitive sequelae, and nocturnal
sweating were significantly associated with the COVID-19 experience when compared
with the controls.
Conclusions: We found that at the time of interview almost three-quarters of children
reported at least one persistent symptom, but the majority of patients (53%) had two or
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more concurrent symptoms. The comparison group’s inclusion in the study allowed us
to identify that symptom persistence is more apparent with COVID-19 than any other
non-SARS-CoV-2 infection. More research is needed to distinguish the symptoms of long
COVID from pandemic-associated complaints. Each persistent symptom is important in
terms of child well-being during COVID-19 recovery.
Keywords: COVID-19, SARS-CoV-2, pediatrics, clinical sequelae, viral
INTRODUCTION
Since March 2020, when theWorld Health Organization (WHO)
declared a global pandemic due to the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), an overwhelming
volume of information related to coronavirus disease 2019
(COVID-19) has been published. At the beginning of the
pandemic, only acute presentation of COVID-19 was described.
In recent months, however, attention has been increasingly
focused on its long-term consequences. Many COVID-19 patient
advocacy groups, for those identifying themselves as “long-
haulers,” have contributed to the recognition of post-acute
COVID-19, and have forced the medical society to continue to
expand the current research into the underlying pathophysiology,
consequences, and rehabilitation options for affected patients.
According to the UK’s National Institute for Health and Care
Excellence’s (NICE) suggested definition, “long COVID” is a
general term describing the signs and symptoms which persist
or develop after acute COVID-19, and it includes two sub-
domains according to timeframe. Firstly, ongoing symptomatic
COVID-19 is defined as symptoms persisting 4–12 weeks from
the onset of the first acute symptoms. Secondly, if symptoms
extend beyond 12 weeks, post-COVID-19 syndrome can be
diagnosed (1, 2). Up to this point, there has been no consensus
on a definition of long COVID, so timeframe, terminology,
and classification can vary from one publication to another.
It has been suggested that the definition could be adapted for
different COVID-19 patient groups, taking into consideration
length of hospitalization, predisposing intrinsic (age, gender,
and comorbidities) and extrinsic (biological, psychological, and
social) factors (2–4). At this point, there is no clear case-definition
for long COVID among the pediatric population.
The precise prevalence of long COVID remains unknown,
and the data is heterogeneous, ranging from 10 to 87% in
adults to 4 to 66% in children (5–15). This wide range could be
explained by lack of systematic, long-term follow-ups, with high
variability in terms of age, severity of infection, prevalence of
pre-existing clinical conditions, and characteristics of the clinical
evaluation (since most pediatric studies are based on self- or
parent-reported symptom persistence using questionnaires or
online surveys) (7, 14, 16, 17).
While many publications are discussing long COVID in
adults, the data on children is relatively scarce, since children and
adolescents are generally less severely affected by acute COVID-
19 than adults, leading to the false assumption that late-COVID-
19 sequelae do not affect this patient group (18). However, in
recent months, data on long COVID in pediatric patients has
increasingly been published, giving new insights into the ways
this phenomenon affects children. One Italian cross-sectional
study showed that almost 53% of children had at least one
persistent symptom 120 days or more after a diagnosis of SARS-
CoV-2 infection (11). Similarly, report form Latvia showed that
51% of children had complaints 55 days after a diagnosis of
SARS-CoV-2 infection, with 22% of patients noting 3 or more
persistent simultaneous symptoms (12). Munblit et al. reported
that almost 25% of children included in the study had at least
one persistent symptom 256 days after being discharged from
hospital, but 8.4% of children had complaints about multiple
long-lasting symptoms. In addition, factors including being in an
older age group (6–18 years) and having allergies were identified
as the main risk factors for long COVID, but further in-depth
research is needed to recognize these predisposing factors (10).
According to the latest studies, the most prevalent post-
COVID symptoms in children are fatigue, headache, insomnia,
sensory problems, cognitive sequelae, and post-viral catarrhal
symptoms (i.e., cough, rhinorrhea, and sore throat) (10–14, 19,
20). The nature of long COVID is unpredictable, since persistent
symptoms can be continuous or relapsing and remitting, making
it difficult to establish a diagnose (21). Moreover, most of
the reported persistent symptoms are not specific enough to
separate long COVID from other medical conditions or, more
importantly, pandemic-associated symptoms since the approach
to mediating these symptoms is different.
Recently, Zimmerman et al., published the most
comprehensive review article to date, discussing 14 studies
investigating long COVID symptoms in children, and
highlighting wide heterogeneity and methodological limitations,
while also emphasizing the need to identify risk factors. This
publication is believed potentially to be a turning point for
development of further research in this field (16).
There is an urgent need to conduct further research into
late sequelae of COVID-19, in particular by identifying the risk
factors and mitigators (if any) for the development of long
COVID, as the debate about the risks and benefits of COVID
vaccinations among the pediatric age group intensifies. In
addition, new global health policies related to early rehabilitation
and reintegration possibilities need to be developed as the
number of pediatric “long-haulers” increases (22).
MATERIALS AND METHODS
Study Design and Participants
This was an ambidirectional cohort study focused on a
pediatric population with the aim of identifying the long-
term consequences of SARS-CoV-2 infection in children 1–
6 months after acute COVID-19. It was conducted at the
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Children’s Clinical University Hospital in Latvia, where a
post-acute outpatient service for children after recovery from
COVID-19 was established. The study population of COVID-
19 patients who had been treated in outpatient settings
as well as hospitals was enrolled between July 1, 2020,
and April 30, 2021. Inclusion criteria were: (1) children
aged 1 month to 18 years, (2) history of microbiologically
confirmed (nasopharyngeal swab) SARS-CoV-2 infection or
subsequent seroconversion, (3) acute phase of COVID-19 1–
6 months before enrollment in the study. Exclusion criteria
were: (1) patients with diagnosed Multisystem Inflammatory
Syndrome in Children (MIS-C), (2) the family’s unwillingness
to participate in further follow-up, (3) no contact information
or an inability to get in touch with the family (4) diagnosed
co-infections, (5) COVID-19 onset more than 6 months
previously. Patients or their parents/caregivers/legal guardians
were interviewed “face-to face” according to a specially designed
post-COVID-19 symptom assessment questionnaire, providing
more accurate data collection and options for examining children
during consultation (Supplementary Material 1). The protocol
consisted of four main domains—physical and mental health,
social, and psycho-emotional wellbeing. The questionnaire was
based on previously published literature about long COVID
in adults (5, 6, 8). During the follow-up, besides the post-
acute symptoms, general demographical and epidemiological
characteristics, as well as vaccination status, pre-existing chronic
conditions, and clinical features during the acute phase of SARS-
CoV-2 infection, were also collected.
In addition, between November 1, 2020, and April 30,
2021, patients with other non-SARS-CoV-2 community-acquired
infections were also invited to participate in the study. This
control group consisted of patients treated in outpatient settings
as well as hospitalized children. Inclusion criteria were: (1)
children aged 1 month to 18 years, (2) no history of COVID-
19, (3) clinical and laboratory findings confirming other non-
SARS-CoV-2 infections. Exclusion criteria for the comparison
group were: (1) confirmed SARS-CoV-2 infection, (2) the
family’s unwillingness to participate in further follow-up, (3)
no contact information or an inability to get in touch with
the family. Eligible subjects in the comparison group or their
parents/caregivers/legal guardians were asked the same interview
questions as those in the cohort (Supplementary Material 2).
All interviews were carried out by our team of researchers
involved in the study. The questionnaire was paper-based and
written in Latvian. After interviews, data was transferred from
questionnaires to MS Excel. Before the interview, caregivers
had to provide written consent. The Ethics Committee
of Riga Stradins University reviewed and approved the
study protocol questionnaire and informed consent forms
(approval No. 6-1/07/35).
Definitions and Outcome Variables
To identify the long-term consequences of SARS-CoV-2
infection, we defined long COVID according to NICE’s proposed
definition as symptom persistence extending beyond 4 weeks
from the onset of the first COVID-19 symptoms or a positive
PCR test (1). Taking into consideration that patients in the
study were enrolled in various time points (from 1 to 6 months
after acute SARS-CoV-2 infection), all NICE’s proposed clinical
definitions were used throughout the manuscript according
to timeframe.
Persistent symptoms were classified according to involved
organ systems, including general sequelae, respiratory,
cardiovascular, gastrointestinal, musculoskeletal, dermatological,
neurological, and cognitive complaints.
Procedure
Families whose children had recovered from SARS-CoV-2
infection were identified and invited to participate in the study
in various direct and indirect ways. One of the first attempts to
address the public directly was via a hospital communication
campaign in the media (television, radio, and online news
services). In this way, we invited parents to apply for their
children to have an in-depth evaluation and long-term medical
surveillance after SARS-CoV-2 infection. As well as the public,
members of various professional medical associations also were
asked to refer their pediatric COVID-19 patients for follow-up
appointments in our hospital. In collaboration with the Disease
Prevention and Control Center of Latvia, we also had direct
contact with various general practitioners in whose practices
confirmed pediatric COVID-19 outpatients had been treated, to
offer our follow-up service. Finally, we co-operated with regional
hospitals in various cities across Latvia (Valmiera, Kraslava, and
Jekabpils), making it possible for our research team to organize
regional consultations, so that we could help and support long
COVID patients outside Riga.
The comparison group patients were included in the study in
twoways. Firstly, children and their parents who had been treated
in the Children’s Clinical University Hospital due to their illness,
were directly addressed and invited to participate. Secondly,
direct contact with general practitioners in various regions of
Latvia was established to invite pediatric patients to participate
in the study.
Statistical Analysis
Statistical analysis was performed using Statistical Package for
the Social Sciences (SPSS) version 23.0 (IBM SPSS Corp.).
Statistical significance was considered as p < 0.05. Standard
methods [mean, standard deviation (SD), median for continuous
variables, frequencies (expressed as percentages) for categorical
variables] were used for descriptive statistics. Chi square or
Fisher exact tests were used to check the significance of stratified
frequencies of dependent variables between cases and controls.
The Kolmogorov–Smirnov test was used to check whether the
continuous variables met the criteria of normal distribution.
The Mann–Whitney U-test was used to check the differences in
continuous dependent variables between cases and controls. To
check the impact of differences in age among cases and controls
on the odds of post-acute and long COVID-19 symptoms,
the adjustment was performed using binary and multinomial
logistic regressions.
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RESULTS
Overall, 239 COVID-19 patients were invited to participate in
the study. Three declined to take part, and in all 236 COVID-
19 patients with confirmed SARS-CoV-2 infection (positive
PCR test or retrospective seroconversion) were enrolled. Of all
the patients, 221 were symptomatic, but 15 children had no
symptoms during the acute COVID-19 phase. Epidemiological
data analysis showed that 80.1% (N = 189) of children had
known contact with a SARS-CoV-2-positive person before acute
symptom onset, but only 7.6% (N = 18) of patients had a history
of recent travel. The median age of the study group was 10.0
years [Interquartile range (IQR), 5–14 years; range, 1 month−18
years], 55.5% (N = 131) of patients were boys. 86.9% (N = 205)
of children were outpatients with mild disease, but 13.1 % (N
= 31) had moderate or severe disease requiring hospitalization.
The mean length of hospital stay was 3.8 (SD, 5.0) days. None
of the hospitalized patients required admission to the Pediatric
Intensive Care Unit (PICU). Fifty-two children (22%) had
known pre-existing comorbidities. The most noted conditions
were bronchial asthma, gastrointestinal disorders, psychiatric
disorders, and epilepsy. No co-infections were diagnosed in the
study group. Median follow-up time from acute symptom onset
was 73.5 days (IQR; 43–110 days).






N % N % N %
Median (interquartile range) age,
years
10.0 (14.0–5.0) 2.0 (6.0–1.0) <0.001 6.0 (12.0–2.0)
Age group
1–11 months 18 7.6 13 9.2 <0.001 31 8.2
1–4 years 34 14.4 78 54.9 112 29.6
5–9 years 59 25.0 38 26.8 97 25.7
10–14 years 71 30.1 10 7.0 81 21.4
15–18 years 54 22.9 3 2.1 57 15.1
Sex
Male 131 55.5 76 53.5 0.71 207 54.8
Female 105 44.5 66 46.5 171 45.2
Vaccination
Seasonal influenza 26 11.9 24 17.6 0.13 50 14.1
BCG 233 98.7 – – – 233 98.7
MMR 208 95.4 – – – 208 95.4
Comorbidities
Epilepsy 5 2.1 1 0.7 0.42 6 1.6
Gastrointestinal disorders 8 3.4 2 1.4 0.49 10 2.6
Bronchial asthma 17 7.2 10 7.0 0.95 27 7.1
Allergies 2 0.8 6 4.2 0.06 8 2.1
Congenital heart diseases 0 0 4 2.8 0.02 4 1.1
Atopic dermatitis 2 0.8 3 2.1 0.37 5 1.3
Rheumatic disorders 1 0.4 0 0 1.00 1 0.3
Cystic fibrosis 3 1.3 0 0 0.30 3 0.8
Urological disorders 1 0.4 1 0.7 1.00 2 0.5
Psychiatric disorders 6 2.5 0 0 0.09 6 1.6
Neurologic disorders 1 0.4 3 2.1 0.15 4 1.1
Congenital anomalies 3 1.3 0 0 0.30 3 0.8
Post-acute follow-up characteristics
Days since symptoms onset, median
(interquartile range)
73.5 (110.0–43.0) 69.0 (84.0–58.0) 0.36 70.0 (100.25–48.5)
Persistent symptoms
None 65 30.0 97 75.2 <0.001 162 46.8
1 35 16.1 16 12.4 51 14.7
2 19 8.8 10 7.8 29 8.4
≥3 98 45.2 6 4.7 104 30.1
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FIGURE 1 | Prevalence (%) of COVID-19 associated symptoms in acute and post-acute phase. *Symptoms combined as they are similar.
In all, 142 comparison group patients were also enrolled in
the study. The median age was 2 years (IQR, 1–6 years; range
1 month−17 years), 53.5% (N = 76) were male. 57.7% (N =
82) were outpatients, but 42.3% (N = 60) of controls were
treated in hospital with mean length of hospitalization being 3.9
(SD, 3.9) days. In this group, 16.9% (N = 24) of patients had
known comorbidities. Bronchial asthma, allergies, and congenital
heart disease were the most reported pre-existing conditions. The
most often diagnosed non-SARS-CoV-2 community-acquired
infections among the controls were the common cold (38.1%,
N = 54), pharyngotonsillitis (21.8%, N = 31), gastrointestinal
infections (19.7%, N = 28), urinary tract infections (8.5%, N
= 12), pneumonia (3.5%, N = 5) and bacterial infections of
unknown origin (3.5%, N = 5). Median follow-up time since
acute symptom onset was 69 days (IQR, 58–84 days). There were
significant statistical differences in age between the patients and
controls (p < 0.001). Table 1 outlines the demographical data,
comorbidities, and persistent symptom distribution across both
study groups.
At the time of the interview, only 30% (N = 65) of children
had returned to their previous state of health, with no long
COVID complaints. Most pediatric COVID-19 survivors (70%,
N = 152) reported at least one persistent symptom, but more
than half of the patients (54%, N = 117) noted multiple long-
lasting symptoms, with an alarming tendency to experience
three or more symptoms at the same time (45.2%, N = 98).
Generally, the most reported complaints among COVID-19
patients concerned persistent fatigue (25.2%, N = 59), cognitive
sequelae including irritability (24.3%, N = 57), mood changes
(23.3%, N = 55), and impaired attention (16.9%, N = 40),
as well as headaches (16.9%, N = 40), rhinorrhea (16.1%, N
= 38), coughing (14.4%, N = 34), and disturbed taste and/or
smell (12.3%, N = 29). Comparing the symptom spectrum in
the acute infectious and long COVID phases, it was evident
that catarrhal symptoms such as fever, rhinorrhea, cough, sore
throat, and wheezing were more dominant in acute SARS-CoV-
2 infection. On the other hand, symptoms as fatigue, headaches,
and dysgeusia/anosmia were still frequently reported after acute
illness. Figure 1 represents COVID-19 symptom distribution in
the acute and post-acute phases.
The prevalence of general symptoms as well as cardiovascular
(except for tachypnoea), musculoskeletal (except for stiffness),
neurological, and cognitive sequelae was significantly higher
in the COVID-19 patient group than among the comparison
group (p < 0.05 for all). In addition, when comparing persistent
symptom prevalence in 5–9-year-olds with ongoing symptomatic
COVID-19 and other non-SARS-CoV-2 infections, we noticed
that a loss of taste and/or smell, as well as cognitive sequelae
(including mood changes, irritability, and anxiety/depression)
were significantly higher in the COVID-19 patient group than
among the comparison group (p < 0.05 for all). Logistic
regression analysis showed that long-term persistent symptoms
such as fever [adjusted Odds Ratio (ORa) = 4.0, 95% confidence
interval (CI): 1.4–11.6, and p = 0.01], fatigue (ORa = 8.7, 95%
CI: 2.5–29.9, and p = 0.001), rhinorrhea (ORa = 2.6, 95%
CI: 1.3–5.4, and p = 0.008), loss of taste and/or smell (ORa
= 11.2, 95% CI: 1.4–89.1, and p = 0.02), headaches (ORa =
12.9, 95% CI: 1.7–99.6, and p = 0.01), cognitive sequelae, as
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TABLE 2 | Prevalence (%) of persistent symptoms in patients with COVID-19 and other non-SARS-CoV-2 infections and age-adjusted associations between COVID-19
status and persistent symptoms.
Symptoms of long COVID 1–6






p-values* ORa** 95% CI*** p-values
N % N %
General sequelae
Fever 31 13.1 5 3.5 0.002 4.0 1.4–11.6 0.01
37.5–38◦C 4 1.7 1 0.7 0.84 1.7 0.2–17.2 0.64
38.1–39.0◦C 1 0.4 1 0.7 1.3 0.1–24.0 0.86
Fatigue 59 25.2 3 2.1 <0.001 8.7 2.5–29.9 0.001
Respiratory sequelae
Cough 34 14.4 18 12.7 0.64 1.9 0.9–3.9 0.07
Sore throat 12 5.1 2 1.4 0.07 3.5 0.7–17.7 0.13
Wheezing 4 1.7 0 0 0.30 – – –
Rhinorrhea 38 16.1 16 11.3 0.19 2.6 1.3–5.4 0.008
Shortness of breath (at rest) 11 4.7 1 0.7 0.04 2.1 0.2–18.4 0.49
Shortness of breath (with
physical activities)
17 7.2 0 0 0.001 – – –
Otorhinolaryngological sequelae
Difficulty swallowing 2 0.8 0 0 0.53 – – –
Voice changes 6 2.5 0 0 0.09 – – –
Speech disturbances 3 1.3 0 0 0.30 – – –
Tinnitus 9 3.8 0 0 0.02 – – –
Cardiovascular sequelae
Heart rhythm disturbances 12 5.1 0 0 0.005 – – –
Orthostatic intolerance 20 8.5 0 0 <0.001 – – –
Tachypnoea 6 2.5 0 0 0.09 – – –
Gastrointestinal sequelae
Diarrhea 10 4.2 2 1.4 0.22 4.1 0.8–21.2 0.09
Vomiting/nausea 7 3.0 1 0.7 0.27 6.2 0.6–60.9 0.12
Loss of appetite 20 8.5 7 4.9 0.20 2.5 0.9–6.7 0.07
Body weight changes 20 8.5 3 2.1 0.01 2.3 0.6–8.7 0.22
Musculoskeletal sequelae
Muscle pain 16 6.8 0 0 0.002 – – –
Muscle spasms 8 3.4 0 0 0.03 – – –
Joint pain 19 8.1 0 0 0.001 – – –
Stiffness 5 2.1 0 0 0.16 – – –
Neurological sequelae
Loss of taste and/or smell 29 12.3 1 0.7 <0.001 11.2 1.4–89.1 0.02
Dizziness 21 8.9 0 0 <0.001 – – –
Headache 40 16.9 1 0.7 <0.001 12.9 1.7–99.6 0.01
Photophobia 12 5.1 0 0 0.005 – – –
Cognitive sequelae
Difficulties to concentrate 40 16.9 1 0.7 <0.001 13.6 1.7–105.3 0.01
Impaired memory 24 10.2 1 0.7 <0.001 7.3 0.9–58.9 0.06
Impaired attention 40 16.9 1 0.7 <0.001 19.0 2.4–147.5 0.005
Mood changes 55 23.3 3 2.1 <0.001 16.0 4.6–55.2 <0.001
Irritability 57 24.3 3 2.1 <0.001 16.0 4.7–55.9 <0.001
Anxiety/depression 31 13.1 0 0 <0.001 – – –
Dermatologic sequelae
Hair loss 6 2.5 0 0 0.09 – – –
(Continued)
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TABLE 2 | Continued
Symptoms of long COVID 1–6






p-values* ORa** 95% CI*** p-values
N % N %
Other symptoms
Enlarged lymph nodes 6 2.5 0 0 0.08 – – –
Nocturnal sweating 23 9.7 1 0.7 <0.001 16.7 2.1–130.4 0.007
Menstrual disturbances 5 7.8 0 0 0.33 – – –
*p-values for univariate analysis (Chi square or Fisher’s exact test).
**aOR, adjusted odds ratio, adjusted for age.
***95% CI, 95% confidence interval.
well as nocturnal sweating (ORa = 16.7, 95% CI: 2.1–130.4,
and p = 0.007) were significantly associated with COVID-
19 experience. Detailed information about persistent symptom
prevalence and age-adjusted associations between COVID-19
status and persistent symptoms is presented in Table 2.
Comparing persistent symptom frequencies among
hospitalized and non-hospitalized COVID-19 patients, in
the former group children complained significantly more often
of prolonged catarrhal symptoms, including coughing (32.3%,
N = 10; vs. 11.7%, N = 24), rhinorrhea (41.9%, N = 13; vs.
12.2%, N = 25), as well as shortness of breath with physical
activities (12.9%, N = 4; vs. 6.3%, N = 13). Interestingly, speech
disturbances (6.5%, N = 2 vs. 0.5%, N = 1) and body weight
changes (22.6%, N = 7; vs. 6.3%, N = 13) were also more
prevalent in hospitalized patients. When sexes are compared,
long-COVID symptoms tended to be more frequent among
female patients. This tendency was prevalent across all long-term
symptom subgroups, with the most significant dominance in
cognitive and neurological sequelae (see Table 3).
Comparing the prevalence of persistent symptoms across
various age groups, among infants and toddlers, parents
complained most frequently about persistent upper respiratory
symptoms such as coughing (11.1%, N = 2 and 29.4%, N
= 10) and rhinorrhea (33.3%, N = 6 and 32.4%, N = 11).
Additionally, COVID-associated prolonged complaints such as
diarrhea (11.1%, N = 2) and nocturnal sweating (22.2%, N
= 4) were more often seen in infants than in any other
age group. In older children, the most prevalent persistent
symptoms were fatigue and cognitive disturbances, as well as
neurological sequelae. Pre-schoolers and school-age children had
post-COVID-associated irritability (27.6%, N = 16) and mood
changes (27.1%, N = 16) among their most frequently reported
symptoms. Interestingly, the prevalence of persistent fatigue
and cognitive complaints increased considerably according to
the study’s age groups, with the highest rates seen among
teenagers (14.7%, N = 5; 1–4-year-olds vs. 37.0%, N = 20;
15–18-year-olds; p = 0.04). Among children aged 10–14 years
old, mood swings (29.6%, N = 21) were the most observed
cognitive complaint. In contrast, in adolescents, cognitive
disturbances including difficulty in concentrating (27.8%, N
= 15) and an inability to focus their attention (24.1%, N =
13) were the most reported persistent symptoms; thus, many
adolescents admitted that their performance at school had been
seriously affected.
Taking into the consideration the timeframe of patient
enrollment in the study, 105 pediatric COVID-19 patients were
diagnosed with post-COVID-19 syndrome. Most frequently
reported symptoms were irritability (27.6%, N = 29), mood
changes (26.7%, N = 28) and fatigue (19.2%, N = 20).
Interestingly, no statistical differences were seen among most
reported persisting symptoms before and after 12-week cut-
off point (with exception of heart rhythm disturbances, where
statistically significant fall from 7.6% (N = 10) to 1.9% (N = 2)
was seen (see Table 3).
DISCUSSION
Although research into long COVID among pediatric population
is ongoing, and new information is published at tremendous
speed all the time, our research has identified the significant
number of children who experience long COVID. We found
that 70% of children experienced long-term symptoms and,
disturbingly, the majority of patients (53%) reported two or
more concurrent symptoms. When attributing our pediatric
population with symptom persistence (N = 152, 70%) to the
total number of SARS-CoV-2 infected children in Latvia (as of
July 27, 13,912 children had confirmed SARS-CoV-2 infection),
it seems that only 1.09% of children infected with SARS-CoV-
2 infection experienced persistent symptoms. We believe that
this assumption could be representative, since our hospital is
the only tertiary-level pediatric medical institution in Latvia in
which a post-acute outpatient service for children recovering
from COVID-19 could be established, and most children with
long COVID are believed to have responded to our call to
participate in the study. Long-term complaints were observed
not only in hospitalized patients, but also in outpatients with
asymptomatic or mild illness, emphasizing the variable nature
of long COVID (23). Significantly, our study, similarly, to
Australian data, refutes a serious misconception that if children
get asymptomatic or mild SARS-CoV-2 infection, they aren’t at
risk of persistent post-acute symptoms (20). On the contrary, it
is evident that long COVID can affect anyone, whatever their
age. According to recent data published by the Office of National





















































N = 236 N = 205 N = 31 N = 52 N = 184 N = 105 N = 131 N = 18 N = 34 N = 59 N = 71 N = 54 N = 131 N = 105
Fever 31 (13.1) 27 (13.2) 4 (12.9) 6 (11.5) 25 (13.6) 16 (15.2) 15 (11.5) 2 (11.1) 5 (14.7) 6 (10.2) 11 (15.5) 7 (13.0) 19 (14.5) 12 (11.4)
37.5◦C−38◦C 4 (1.7) 4 (2.0) 0 0 4 (2.0) 1 (1.0) 3 (2.3) 0 0 2 (3.4) 2 (2.8) 0 1 (0.8) 3 (2.9)
38.1◦C−39.0◦C 1 (0.4) 0 1 (3.2) 0 1 (0.5) 1 (1.0) 0 1 (5.6) 0 0 0 0 0 1 (1.0)
Fatigue 59 (25.2) 53 (26.0) 6 (20.0) 17 (33.3) 42 (23.0) 33 (31.7) 26
(20.0)*
2 (11.8) 5 (14.7) 10 (17.2) 22 (31.0) 20
(37.0)*
39 (30.0) 20 (19.2)
Cough 34 (14.4) 24 (11.7) 10 (32.3)* 10 (19.2) 24 (13.0) 18 (17.1) 16 (12.2) 2 (11.1) 10 (29.4) 9 (15.3) 10 (14.1) 3 (5.6)* 15 (11.5) 19 (18.1)
Sore throat 12 (5.1) 9 (4.4) 3 (9.7) 2 (3.8) 10 (5.4) 7 (6.7) 5 (3.8) 0 1 (2.9) 5 (8.5) 5 (7.0) 1 (1.9) 7 (5.3) 5 (4.8)
Wheezing 4 (1.7) 3 (1.5) 1 (3.2) 3 (5.8) 1 (0.5)* 3 (2.9) 1 (0.8) 0 0 1 (1.7) 3 (4.2) 0 2 (1.5) 2 (1.9)
Rhinorrhea 38 (16.1) 25 (12.2) 13 (41.9)* 11 (21.2) 27 (14.7) 24 (22.9) 14
(10.7)*
6 (33.3) 11 (32.4) 8 (13.6) 6 (8.5) 7 (13.0)* 21 (16.0) 17 (16.2)
Shortness of
breath at rest




17 (7.2) 13 (6.3) 4 (12.9) 8 (15.4) 9 (4.9)* 13 (12.4) 4 (3.1)* 1 (5.6) 0 0 11 (15.5) 5 (9.3)* 9 (6.9) 8 (7.6)
Difficulty
swallowing
2 (0.8) 2 (1.0) 0 0 2 (1.1) 2 (1.9) 0 0 0 1 (1.7) 1 (1.4) 0 0 2 (1.9)
Voice changes 6 (2.5) 5 (2.4) 1 (3.2) 1 (1.9) 5 (2.7) 5 (4.8) 1 (0.8) 1 (5.6) 1 (2.9) 2 (3.4) 2 (2.8) 0 2 (1.5) 4 (3.8)
Speech
disturbances
3 (1.3) 1 (0.5) 2 (6.5)* 2 (3.8) 1 (0.5) 3 (2.9) 0 0 0 0 2 (2.8) 1 (1.9) 0 3 (2.9)
Tinnitus 9 (3.8) 8 (3.9) 1 (3.2) 4 (7.7) 5 (2.7) 6 (5.7) 3 (2.3) 0 0 0 6 (8.5) 3 (5.6) 5 (3.8) 4 (3.8)
Heart rhythm
disturbances
12 (5.1) 10 (4.9) 2 (6.5) 5 (9.6) 7 (3.8) 10 (9.5) 2 (1.5)* 0 0 0 7 (9.9) 5 (9.3)* 10 (7.6) 2 (1.9)*
Orthostatic
intolerance
20 (8.5) 18 (8.8) 2 (6.5) 7 (13.5) 13 (7.1) 14 (13.3) 6 (4.6)* 0 0 0 10 (14.1) 10
(18.5)*
13 (9.9) 7 (6.7)
Tachypnoea 6 (2.5) 4 (2.0) 2 (6.5) 2 (3.8) 4 (2.2) 5 (4.8) 1 (0.8) 0 1 (2.9) 0 4 (5.6) 1 (1.9) 4 (3.1) 2 (1.9)
Diarrhea 10 (4.2) 7 (3.4) 3 (9.7) 4 (7.7) 6 (3.3) 4 (3.8) 6 (4.6) 2 (11.1) 2 (5.9) 2 (3.4) 3 (3.4) 1 (1.9) 6 (4.6) 4 (3.8)
Vomiting/nausea 7 (3.0) 6 (2.9) 1 (3.2) 1 (1.9) 6 (3.3) 5 (4.8) 2 (1.5) 0 2 (5.9) 1 (1.7) 2 (2.8) 2 (3.7) 4 (3.1) 3 (2.9)
Loss of appetite 20 (8.5) 17 (8.3) 3 (9.7) 4 (7.7) 16 (8.7) 13 (12.4) 7 (5.3) 1 (5.6) 7 (20.6) 4 (6.8) 3 (4.2) 5 (9.3) 14 (10.7) 6 (5.7)
Body weight
changes
20 (8.5) 13 (6.3) 7 (22.6)* 5 (9.6) 15 (8.2) 12 (11.4) 8 (6.1) 2 (11.1) 1 (2.9) 3 (5.1) 7 (9.9) 7 (13.0) 7 (5.3) 13 (12.4)
Muscle pain 16 (6.8) 14 (6.8) 2 (6.5) 7 (13.5) 9 (4.9) 11 (10.5) 5 (3.8)* 0 1 (2.9) 5 (8.5) 7 (9.9) 3 (5.6) 10 (7.6) 6 (5.7)
Muscle spasms 8 (3.4) 6 (2.9) 2 (6.5) 2 (3.8) 6 (3.3) 6 (5.7) 2 (1.5) 0 0 1 (1.7) 4 (5.6) 3 (5.6) 3 (2.3) 5 (4.8)
Joint pain 19 (8.1) 18 (8.8) 1 (3.2) 5 (9.6) 14 (7.6) 11 (10.5) 8 (6.1) 0 1 (2.9) 4 (6.8) 8 (11.3) 6 (11.1) 13 (9.9) 6 (5.7)







































































































N = 236 N = 205 N = 31 N = 52 N = 184 N = 105 N = 131 N = 18 N = 34 N = 59 N = 71 N = 54 N = 131 N = 105
Loss of taste
and/or smell
29 (12.3) 28 (13.7) 1 (3.2) 3 (5.8) 26 (14.1) 17 (16.2) 12 (9.2) 0 2 (5.9) 7 (11.9) 12 (16.9) 8 (14.8) 17 (13.0) 12 (11.4)
Dizziness 21 (8.9) 20 (9.8) 1 (3.2) 8 (15.7) 13 (7.1) 19 (18.1) 2 (1.5)* 0 1 (2.9) 0 9 (12.7) 11
(20.4)*
14 (10.8) 7 (6.7)
Headache 40 (16.9) 38 (18.5) 2 (6.5) 11 (21.2) 29 (15.8) 31 (29.5) 9 (6.9)* 0 1 (2.9) 9 (15.3) 16 (22.5) 14
(25.9)*
24 (18.3) 16 (15.2)
Photophobia 12 (5.1) 11 (5.4) 1 (3.2) 3 (5.8) 9 (4.9) 9 (8.6) 3 (2.3)* 0 1 (2.9) 1 (1.7) 3 (4.2) 7 (13.0) 7 (5.3) 5 (4.8)
Difficulties to
concentrate
40 (16.9) 36 (17.6) 4 (12.9) 13 (25.0) 27 (14.7) 26 (24.8) 14
(10.7)*
0 2 (5.9) 7 (11.9) 16 (22.5) 15
(27.8)*
21 (16.0) 19 (18.1)
Impaired memory 24 (10.2) 21 (10.2) 3 (9.7) 10 (19.2) 14 (7.6)* 15 (14.3) 9 (6.9) 0 1 (2.9) 4 (6.8) 12 (16.9) 7 (13.0) 10 (7.6) 14 (13.3)
Impaired attention 40 (16.9) 34 (16.6) 6 (19.4) 14 (26.9) 26 (14.1)* 26 (24.8) 14
(10.7)*
0 4 (11.8) 8 (13.6) 15 (21.1) 13 (24.1) 20 (15.3) 20 (19.0)
Mood changes 55 (23.3) 47 (22.9) 8 (25.8) 18 (34.6) 37 (20.1)* 30 (28.6) 25 (19.1) 0 10 (29.4) 16 (27.1) 21 (29.6) 8 (14.8)* 27 (20.6) 28 (26.7)
Irritability 57 (24.3) 49 (24.0) 8 (25.8) 16 (31.4) 41 (22.3) 32 (30.5) 25
(19.2)*
1 (5.6) 10 (29.4) 16 (27.6) 20 (28.2) 10 (18.5) 28 (21.5) 29 (27.6)
Anxiety/depression 31 (13.1) 25 (12.2) 6 (19.4) 10 (19.2) 21 (11.4) 22 (21.0) 9 (6.9)* 0 1 (2.9) 7 (11.9) 14 (19.7) 9 (16.7) 14 (10.7) 17 (16.2)
Hair loss 6 (2.5) 4 (2.0) 2 (6.5) 3 (5.8) 3 (1.6) 6 (5.7) 0* 0 1 (2.9) 0 5 (7.0) 0 2 (1.5) 4 (3.8)
Enlarged lymph
nodes
6 (2.5) 5 (2.4) 1 (3.2) 1 (1.9) 5 (2.7) 2 (1.9) 4 (3.1) 0 3 (8.8) 0 1 (1.4) 2 (3.7) 1 (0.8) 5 (4.8)
Nocturnal
sweating
23 (9.7) 18 (8.8) 5 (16.1) 10 (19.2) 13 (7.1)* 12 (11.4) 11 (8.4) 4 (22.2) 2 (5.9) 8 (13.6) 7 (9.9) 2 (3.7) 12 (9.2) 11 (10.5)
Menstrual
disturbances
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Statistics (in the United Kingdom), 12–15% of children may have
symptoms persisting up to 5 weeks after an acute SARS-CoV-2
infection (24).
Crucially, the inclusion of the comparison group in the study
allowed us to prove that symptom persistence is more evident
with COVID-19 than any other non-SARS-CoV-2 infection.
This conclusion resonates with all three outbreaks of highly
pathogenic human coronaviruses (hCoVs) (25, 26). For example,
Chinese researchers found that 1–3 months after SARS-CoV-
1 infection, pediatric patients reported increased thinning of
hair, decreased exercise tolerance, vague muscle weakness,
emotional lability, and a transient decrease in attention span
post-recovery (26). Up to this point, few viral infections had the
potential to cause persistent symptoms in children. The most
frequently discussed infection with late sequelae is Infectious
Mononucleosis (IM), caused by the Epstein-Barr virus (EBV).
For instance, research from the United States has revealed
that 13% of adolescents met the criteria for Chronic Fatigue
Syndrome (CFS) 6 months after acute EBV infection, but 7%, and
4% of children reported symptom persistence even as long as 12
and 24 months after acute infection, respectively (27).
Fatigue was the most frequently reported persisting symptom
in our study—one in four children complained of this long-
term effect. And many publications have proven that fatigue is
the prevailing symptom across all age groups. Research from
Russia showed that persistent fatigue was present in 10.6%
of children, with a median follow-up time of 268 days (10).
In contrast, a cross-sectional observational study from the
Netherlands presented alarming data showing that up to 87%
of pediatric COVID-19 survivors experienced persistent fatigue
(28). Similar data has been reported from Sweden, showing
fatigue as the most common symptom in hospitalized children,
with a median follow-up time of 219 days (29). Among the adult
population, a similar tendency has been observed, with 63% of
hospitalized patients reporting persistent fatigue 6 months after
acute COVID-19 (30).
Cognitive sequelae represented the second-most prevalent
symptom group, with irritability and mood swings being the
most frequent complaints. In another study, assessing 510
pediatric patients with long COVID, parents reported that
∼55% of children had three or more mental health issues
(31). In adults, the psychosocial distress and neuropsychiatric
symptoms were more prominent, and recently there has been a
growing awareness of these late-onset consequences of COVID-
19. According to a recently published systematic review and
meta-analysis by Badenoch et al. (32), sleep disturbance, fatigue,
objectively measured cognitive impairment, anxiety, and Post-
Traumatic Stress Disorder (PTSD) were the most common
cognitive/neuropsychiatric symptoms in adults. In an Italian
cohort of 402 adult COVID-19 survivors, 56% of patients
showed at least one long-term psychiatric symptom (such as
PTSD, depression, anxiety, insomnia, and obsessive-compulsive
symptomatology) 1 month after hospitalization (33).
Many children in our study also had persistent respiratory
symptoms, including rhinorrhea (16.1%) and coughing (14.4%),
even though respiratory sequelae in general (dyspnea, cough,
and chest pain) is more prevalent in adults (30, 34–38). A
similar pattern was seen in another Italian study, in which
14.7% of the pediatric population had prolonged respiratory
symptoms, including rhinorrhea (12.4%), chest tightness (6.2%),
and persistent coughing (5.4%) (11). In addition, Australian
researchers also found that the most common post-acute
COVID-19 symptom in children was a mild post-viral cough
(4%), lasting from 3 to 8 weeks from the time of symptom
onset (20). We observed that upper respiratory-tract symptoms
were most commonly reported among infants and preschoolers.
This could be explained by the overwhelming volume of
information available in the media about COVID-19, with the
main emphasis on respiratory symptoms as the most common
ones in children, thus shifting parents’ focus on to the pandemic
while neglecting other etiological agents of the common cold.
Parents also emphasized that 13.1% of children had an elevated
body temperature (as high as 37.5◦C). As far as we are aware,
fever (>37.5◦C) is not widely associated with long COVID in
children or adults. Tenforde et al. (34) have reported that in adult
patients who complained about fever and chills on the day of
testing for SARS-CoV-2, these symptoms were resolved in 97 and
96% of respondents within 14–21 days, respectively. Similarly,
extensive reports on long-term fever in children are not available.
Research from the Netherlands has shown that only two children
from its study group had persistent fever (28).
Even though our study highlighted a wide spectrum of
reported persistent COVID-19 symptoms with differences
among the various age groups, the causation and correlation
between late sequelae and SARS-CoV-2 infection remains
unexplored, since biological underpinnings of persistent
COVID-19 symptoms have not been studied sufficiently (36).
Many of the reported long-COVID symptoms are non-specific,
thus making it difficult to distinguish long COVID from
pandemic-associated symptoms caused by lockdown measures
(i.e., restricted socializing, school closures), which have been
shown to have negative effects on the well-being and mental
health of children and adolescents (16, 32, 39). In order to prove
the correlation between SARS-CoV-2 infection and symptom
persistence in children, it is crucial to carry out research with
matched control groups and validated research tools, including
objective functional testing and imaging, since self-reported
symptoms may be difficult to validate (14, 16, 29).
Up to now, only five in pediatric population-based studies
with included control groups have been published (13–15, 40,
41). The long-COVID prevalence rates are quite different, since
only three of these studies found persistent symptoms to be more
common in children with confirmed SARS-CoV-2 infection
(13, 15, 40). The spectrum of the most commonly reported
persistent symptoms was compatible with our study, since
fatigue, headaches and prolonged respiratory symptoms were
the most commonly reported complains. All these studies used
self-or parent- reported persistent symptom questionnaires or
online surveys, thus lacking the previously mentioned objective
assessment. Furthermore, the follow-up time was variable in
these studies, therefore they do not represent unified data on
persistent symptom duration in children.
Recently, there have been some groundbreaking objective
laboratory and imaging studies showing that long-term tissue
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damage, pathological inflammation, or dysimmune reactions
may drive long COVID (23, 42–44). In addition, advanced
imaging techniques can now identify possible underlying
pathophysiological abnormalities of long COVID. For instance,
Buonsenso et al. (45) have described using single-photon
emission computed tomography with co-registered CT
(SPECT/CT) to identify pulmonary circulation dysfunction
with possible lung microvascular or endothelial damage in a
14-year-old girl with long COVID symptoms. Moreover, there
have been novel indicators that a [18F]-FDG brain PET scan’s
visualized hypometabolic pattern could serve as a biomarker
to help to identify severe or atypical forms of long COVID in
children (46).
Undoubtedly, pediatric patients and their parents have
contributed significantly to the recognition of long COVID in
children with many parent-driven advocacy groups campaigning
to draw awareness to this phenomenon, since resistance and
doubts remain in the medical and scientific communities
regarding the acceptance of long COVID in children. As the
number of pediatric “long-haulers” increases, new global health
policies are urgently needed to avoid misdiagnoses of long
COVID and wrongful categorization of patients via an incorrect
diagnosis (such as depression, anxiety, or fibromyalgia) (47).
As far as we are aware, our study is the first to compare
symptom distribution across different age groups. Our study
has highlighted that school-age children, and adolescents
in particular, overwhelmingly complained of cognitive and
neurological sequelae, but parents of infants and preschoolers
more often reported respiratory symptoms. These differences in
symptom distribution could be explained by the fact that older
children could self-report and express their complaints to their
parents and our research team at interview, whereas younger
patients could not differentiate and express their subjective
feelings. All data for younger children was obtained from their
parents, whose judgment about their child’s state of health may
not always have been entirely accurate.
Our study has several strengths. Firstly, our follow-up
was organized in the form of “face-to-face” visits, with the
participation of parents and children themselves, to ensure better
contact and communication with the families involved, and to
provide more accurate data collection and options for examining
children during consultations. Secondly, our study population
included patients from all regions of Latvia, giving a better
understanding of the overall picture across the country. Thirdly,
our cohort consisted of both hospitalized and non-hospitalized
patients, giving an accurate representation of the pediatric
population. Fourthly, we enrolled a comparison group in our
study, allowing us to compare a persistent symptom spectrum
across SARS-CoV-2 and other non-SARS-CoV-2 infections,
and to prove that long-term symptoms were more persistent
with COVID-19.
Our study also faced limitations. Firstly, there was no clear
case definition for long COVID in the pediatric population, thus
making it difficult objectively to define patient inclusion criteria
and follow-up times. Secondly, it was developed based on a non-
validated questionnaire, and no objective parameters were used
in patient evaluation. For reference, we began to design our study
in early April 2020, when the first studies into the potential
long-term consequences in adults began to emerge. Therefore,
our questionnaire was designed according to those first reports.
Thirdly, we started the patient enrolment at the peak of the first
wave of pandemic. As we now look back, we acknowledge that
some of the patients’ reported symptoms could be psychosomatic
or pandemic-associated, and not directly driven by COVID-
19. Fourthly, there was a considerable age difference between
both study groups due to pandemic- associated restrictions,
which affected the homogeneity of our study population. For
information, schools in Latvia were closed during the pandemic,
and the only educational institutions open were day-care centers
and kindergartens. Therefore, most of the children who turned to
hospitals for help or outpatient care due to community-acquired
non-SARS-CoV-2 infections were preschoolers, resulting in a
younger comparison group than the COVID-19 patient group.
Further control group’s expansion and matching for age, sex, and
testing time are needed.
Despite the study’s limitations and pandemic-associated
challenges, we believe that our contribution to long-COVID
research is considerable, and our data may be used for further
studies to continue to explore the nature, and consequences of
long COVID in children. In addition, we are continuing further
patient follow-up with repeated consultations at 12- and 24-
months post-SARS-CoV-2 infection, thereby ensuring broader
insight into persistent symptom distribution and prevalence
among the pediatric population.
CONCLUSIONS
This study highlights that long COVID represents a
serious challenge to the pediatric population. Symptoms
including persistent fatigue, cognitive sequelae, headaches,
anosmia/dysgeusia, and respiratory sequelae were the most
frequently reported complaints of long COVID-19, representing
the wide range of symptoms affecting children. Comparison
group of other non-SARS-CoV-2 infections allowed to
prove that long-term symptoms are more prevalent among
COVID-19 patients.
More research is needed to distinguish symptoms of long
COVID from pandemic-associated complains. Each persistent
symptom is important in terms of child well-being while
recovering from COVID-19.
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